A Phase 1 Randomized, Observer-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 in Healthy Adult Volunteers Administered by Nasal Sprayer and Pipette.
Phase of Trial: Phase I
Latest Information Update: 07 May 2018
At a glance
- Drugs NB 1008 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors BlueWillow Biologics
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.